Bots, editor, reviewer, Administrators
13,951
edits
No edit summary |
No edit summary |
||
Line 519: | Line 519: | ||
'''Myeloproliferative Neoplasms''' | '''Myeloproliferative Neoplasms''' | ||
* [[CYTO-PV]] (2013): Hematocrit thresholds in PV | * [[CYTO-PV]] (2013): Hematocrit thresholds in PV | ||
* [[IRIS]] (2003): Imatinib vs. IFNα/cytarabine in CML | |||
'''Polycythemia Vera''' | '''Polycythemia Vera''' | ||
Line 783: | Line 784: | ||
* [[BRIM-3]] (2011): Vemurafenib in BRAF V600+ melanoma | * [[BRIM-3]] (2011): Vemurafenib in BRAF V600+ melanoma | ||
* [[CheckMate-003]] (2012): Nivolumab in solid tumors | * [[CheckMate-003]] (2012): Nivolumab in solid tumors | ||
'''Myeloproliferative Neoplasms''' | |||
* [[IRIS]] (2003): Imatinib vs. IFNα/cytarabine in CML | |||
'''Prostate Cancer''' | '''Prostate Cancer''' |